mRNA Cancer Vaccines-Messages that Prevail
- PMID: 28401358
- DOI: 10.1007/82_2017_509
mRNA Cancer Vaccines-Messages that Prevail
Abstract
During the last decade, mRNA became increasingly recognized as a versatile tool for the development of new innovative therapeutics. Especially for vaccine development, mRNA is of outstanding interest and numerous clinical trials have been initiated. Strikingly, all of these studies have proven that large-scale GMP production of mRNA is feasible and concordantly report a favorable safety profile of mRNA vaccines. Induction of T-cell immunity is a multi-faceted process comprising antigen acquisition, antigen processing and presentation, as well as immune stimulation. The effectiveness of mRNA vaccines is critically dependent on making the antigen(s) of interest available to professional antigen-presenting cells, especially DCs. Efficient delivery of mRNA into DCs in vivo remains a major challenge in the mRNA vaccine field. This review summarizes the principles of mRNA vaccines and highlights the importance of in vivo mRNA delivery and recent advances in harnessing their therapeutic potential.
Similar articles
-
mRNA Cancer Vaccines.Recent Results Cancer Res. 2016;209:61-85. doi: 10.1007/978-3-319-42934-2_5. Recent Results Cancer Res. 2016. PMID: 28101688 Review.
-
Challenges and advances towards the rational design of mRNA vaccines.Trends Mol Med. 2013 Dec;19(12):705-13. doi: 10.1016/j.molmed.2013.09.002. Epub 2013 Oct 15. Trends Mol Med. 2013. PMID: 24138818 Review.
-
Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Methods Mol Biol. 2013. PMID: 23296938 Review.
-
Tumor vaccination using messenger RNA: prospects of a future therapy.Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.
-
Programming human dendritic cells with mRNA.Methods Mol Biol. 2013;969:111-25. doi: 10.1007/978-1-62703-260-5_8. Methods Mol Biol. 2013. PMID: 23296931 Review.
Cited by
-
Toward rational vaccine engineering.Adv Drug Deliv Rev. 2022 Apr;183:114142. doi: 10.1016/j.addr.2022.114142. Epub 2022 Feb 9. Adv Drug Deliv Rev. 2022. PMID: 35150769 Free PMC article. Review.
-
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.Cancer Treat Rev. 2022 Jun;107:102405. doi: 10.1016/j.ctrv.2022.102405. Epub 2022 May 5. Cancer Treat Rev. 2022. PMID: 35576777 Free PMC article. Review.
-
Combinatorial Immunotherapies for Metastatic Colorectal Cancer.Cancers (Basel). 2020 Jul 12;12(7):1875. doi: 10.3390/cancers12071875. Cancers (Basel). 2020. PMID: 32664619 Free PMC article. Review.
-
Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma.Cancers (Basel). 2022 Jan 17;14(2):448. doi: 10.3390/cancers14020448. Cancers (Basel). 2022. PMID: 35053609 Free PMC article.
-
Novel approaches for the design, delivery and administration of vaccine technologies.Clin Exp Immunol. 2019 May;196(2):189-204. doi: 10.1111/cei.13287. Epub 2019 Apr 8. Clin Exp Immunol. 2019. PMID: 30963549 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
